Second Quarter 2025 Financial Results August 1, 2025 © 2025 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's ability to drive use of Spikevax, mNEXSPIKE and mRESVIA; Moderna's focus on 10 product approvals to drive sales growth; Moderna's 2025 financial framework; Moderna's ability to deliver cost e ...